bioRxivBioinformaticsPreprint
Heli-SMACC: Helicase-targeting SMAll Molecule Compound Collection
Holli‐Joi MartiniD, Mohammad Anwar HossainiD, James WellnitziD, Enes KelestemuriD, Joshua E. HochuliiD, Sumera Parveen, C.H. ArrowsmithiD, Timothy Mark WillsoniD, Eugene N. MuratoviD, Alexander TropshaiD
Abstract
Helicases have emerged as promising targets for the development of antiviral drugs; however, the family remains largely undrugged. To support the focused development of viral helicase inhibitors we identified, collected, and integrated all chemogenomics data for all available helicases from the ChEMBL database. After thoroughly curating and enriching the data with relevant annotations we have created a derivative database of helicase inhibitors which we dubbed Heli-SMACC (Helicase-targeting SMAll Molecule Compound Collection). The current version of Heli-SMACC contains 20,432 bioactivity entries for viral, human, and bacterial helicases. We have selected 30 compounds with promising viral helicase activity and tested them in a SARS-CoV-2 NSP13 ATPase assay. Twelve compounds demonstrated ATPase inhibition and a consistent dose-response curve. The Heli-SMACC database may serve as a reference for virologists and medicinal chemists working on the development of novel helicase inhibitors. Heli-SMACC is publicly available at https://smacc.mml.unc.edu. HighlightsO_LIWe created a curated Helicase-Targeting SMAll Molecule Compound Collection (Heli-SMACC). C_LIO_LIHeli-SMACC covers 29 human, viral, and bacterial helicases. C_LIO_LITwelve of thirty selected compounds demonstrated inhibitory activity in a SARS-CoV-2 NSP13 ATPase Assay. C_LIO_LIHeli-SMACC is freely available online at https://smacc.mml.unc.edu. C_LI TOC Graphic O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=125 SRC="FIGDIR/small/602122v1_ufig1.gif" ALT="Figure 1"> View larger version (36K): org.highwire.dtl.DTLVardef@8e098forg.highwire.dtl.DTLVardef@115cb2borg.highwire.dtl.DTLVardef@1cd9da3org.highwire.dtl.DTLVardef@2870a6_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- organism: virus
- organism: bacteria (other)
- research focus: database / resource
- research focus: benchmarking
- research focus: variant effect prediction
- research focus: drug response / drug discovery
- approach: statistical model
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase
M. A. White, W. Lin, X. Cheng·bioRxiv·Aug 9, 2020
- Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp13 Helicase
R. Beale, A. P. Bertolin, … J. Zeng·bioRxiv·Apr 7, 2021
- Small Molecule Antiviral Compound Collection (SMACC): a database to support the discovery of broad-spectrum antiviral drug molecules.
Holli‐Joi Martin, Cleber Camilo Melo-Filho, … Alexander Tropsha·bioRxiv·Jul 9, 2022
- Structure, Mechanism and Crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase
J. A. Newman, A. Douangamath, … O. Gileadi·Nature CommunicationsPeer-reviewed·Aug 11, 2021
- Using a function-first "scout fragment"-based approach to develop allosteric covalent inhibitors of conformationally dynamic helicase mechanoenzymes
J. R. Ramsey, P. M. M. Shelton, … T. M. Kapoor·bioRxiv·Sep 25, 2023
- Modelling the active SARS-CoV-2 helicase complex as a basis for structure-based inhibitor design
D. Berta, M. Badaoui, … E. Rosta·bioRxiv·Nov 3, 2020